The U.S. Food and Drug Administration is examining unpublished findings by a group of academic researchers, which suggest a potential link between newer diabetes drugs and pancreatic cancer.
Among the drugs being investigated are Merck’s Januvia and Bristol-Myers Squibb’s Byetta, Bloomberg reports.
Researchers called for an investigation after publishing an analysis of insurance records in the medical journal JAMA Internal Medicine. That analysis concluded that diabetics hospitalized with pancreatitis were twice as ...
continue reading...